Table 1. Narcolepsy characteristics of 10 patients with narcolepsy type 1 comorbid with psychosis.
| Case 1 S-925 Spain | Case 2 NUR-055 Spain | Case 3 S-462 Spain | Case 4 S-412 Spain | Case 5 WG France | Case 6 CT France | Case 7 LG France | Case 8 MR France | Case 9 JM France | Case 10 NY France | |
|---|---|---|---|---|---|---|---|---|---|---|
| Gender Male (M)/Female (F) | F | M | F | F | M | M | M | M | M | F |
| Age | 16 | 34 | 38 | 20 | 40 | 48 | 59 | 22 | 30 | 21 |
| BMI | 31.3 | 34.9 | 36.1 | 46.8 | 28.3 | 28.9 | 39.7 | 22 | 27 | 22 |
| Age at sleepiness onset | 16 | 8 | 14 | 7 | 15 | 36 | 30 | 10 | 29 | 12 |
| Age at cataplexy onset | 16 | 10 | na | 8 | 26 | 42 | 33 | 15 | 29 | 12 |
| Cataplexy frequency | 1 per week | >1 per year and <1 per month | na | 1 per month | 1 per year | 1 per week | >1 per day | >1 per day | >1 per day | >1 per year and <1 per month |
| Hypnagogic hallucinations | Yes | No | No | Yes | No | Yes | Yes | Yes | Yes | Yes |
| Sleep paralysis | Yes | Yes | No | No | No | Yes | Yes | Yes | Yes | No |
| MSLT latency, min | na | 0.9 | 0.3 | 4.6 | 5.6 | 2 | 4.5 | 2.6 | 5.4 | 4.2 |
| Number of SOREMPS, n | na | 5 | 3 | 2 | 3 | 5 | 5 | 5 | 3 | 4 |
| HLA DQB1 | DQB1*06:02/03:01 | DQB1*06:02/05:01 | DQB1*06:02 | DQB1*06:02 | DQB1*06:02/03:0X | DQB1*06:02/06:02 | DQB1*0602 | DQB1*0602 | DQB1*0602/0501 | DQB1*0602 |
| CSF hypocretin-1, pg/ml | 88 | na | <10 | <10 | 39 | <10 | na | <10 | <10 | <10 |
| Narcolepsy medication | Fluoxetine 40 mg/d | No drug | Modafinil 200 mg | No drug | No drug | Modafinil 400 mg/d Venlafaxine 75 mg/d | Modafinil 400 mg/d Venlafaxine 300 mg/d | Modafinil 300 mg/d Sodium Oxybate 7 g/d Venlafaxine 75 mg | Pitolisant 40 mg/d | No drug |